The median TMB was 4 mutations/MB for all ROS1+ tumors (n = 259) while it was 4 in NSCLC, 3 in GBM and 5 in breast cancer patients with ROS1 fusions (Table 2). This evidence concerns the gene ROS1 and glioblastoma.